By letter dated June 30, 2021, drug manufacturer Boehringer Ingelheim Pharmaceuticals, Inc. notified covered entities that it will no longer honor all 340B contract pharmacy arrangements, effective August 1, 2021. …
The following press release was posted on Rep. David B. McKinley’s (R-WV-1) website on May 19, 2021. The press release can be accessed by clicking HERE. MCKINLEY APPLAUDS DECISION…
Following a favorable May 17 Letter (the “Letter”) issued by HHS requiring six drug companies to restart 340B pricing on drugs shipped to contract pharmacies or risk civil monetary penalties,…
Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making clear to the manufacturers that their restrictions on access to…
On April 6th, 2021, the New York legislature announced that it was delaying a controversial policy that would require the New York Medicaid program to carve out the pharmacy benefit…
The following article was originally published by the Gotham Gazette. Governor Cuomo has worked hard to cultivate a national reputation as the Emmy Award-winning hero of his own covid reality…
The following article was originally posted in Drug Channels on WETM TV 18’s website, https://www.mytwintiers.com, on December 10, 2020. Trillium Health is an RWC-340B Sustaining Member. On December 1, World…
On December 1, 2020, drug manufacturer Novo Nordisk Inc. announced that, effective January 1, 2021, it “will no longer facilitate ‘bill-to/ship-to’ distribution of 340B product to a contract pharmacy of…
Thanks to efforts by RWC-340B members and other covered entity advocates, 217 members of the House of Representatives signed a bipartisan letter to Health and Human Services (HHS) Secretary Alex…
By letter dated October 30, 2020, Novartis is notifying covered entities that are federal grantees that they will continue to receive 340B discounts at contract pharmacies and, beginning November 16,…